One dose of AbbVie's blockbuster biologic, Humira (adalimumab), in the US equals around six doses of Zydus Cadila's cut-price biosimilar version in terms of the cost of therapy and the Indian firm's product appears to have triggered interesting shifts both in treatment dynamics and the competitive landscape on the domestic market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?